Lytgobi Tablet
Product Images NDC 64842-0127

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Lytgobi (NDC 64842-0127). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Taiho Pharmaceutical Co., Ltd., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel (Blister Card 4mg 21ct)

This is a description for a medication named "NoGesesz1z0s LYTGOBI". Each tablet of this medication contains 4mg of the active ingredient. The daily dose of this medication is 12mg, which means three 4mg tablets are needed to be taken once a day. It is recommended to swallow the tablet whole and not to crush, chew, split, or dissolve it. The manufacturer of this medication is TAIHO ONCOLOGY. There is also a mention of "5 ibatin) aiets", but it is not clear what it refers to as the text is not readable.*

FDA Label Image

Principal Display Panel (Blister Card 4mg 28ct)

LYTGOBI is a medication for oncology. Each tablet contains 4 mg. The recommended daily dose is 16 mg, which is four 4 mg tablets to be taken once a day. The tablets must be swallowed whole and should not be crushed, chewed, split, or dissolved.*

FDA Label Image

Principal Display Panel (Blister Card 4mg 35ct)

Description: This appears to be a set of instructions for using a medication called Nosessszor00 produced by HTAIHO ONCOLOGY. Each tablet contains 4 mg of the medication, and the recommended daily dose is 20 mg. Users are advised to take 5 tablets once a day, and to swallow them whole without crushing, chewing, splitting or dissolving them in any way.*

FDA Label Image

Principal Display Panel (Carton 4mg 21ct)

LYTGOBI is a medication that contains futibatinib in tablet form, with each tablet containing 4mg. The packaging contains a blister card with 21 tablets, which is a 7-day supply. The tablets should be taken once daily, and three 4mg tablets equal a daily dose of 12mg. LYTGOBI can be taken with or without food and at approximately the same time every day. It is important to swallow the tablets whole without crushing, chewing, splitting, or dissolving them. If a dose is missed for more than 12 hours, dosing should be resumed with the next scheduled dose. There are additional unreadable characters present in the text.*

FDA Label Image

Principal Display Panel (Carton 4mg 28ct)

LYTGOBI (futibatinib) tablets are available in a 16 mg daily dose, and the medication is taken orally once daily with four 4 mg tablets. One blister card with 28 tablets is provided, amounting to a 7-day supply. LYTGOBI tablets should be taken with or without food at roughly the same time every day. The tablets should be swallowed whole and not crushed, chewed, split, or dissolved. If a dosage is missed for more than 12 hours, the patient should resume dosing with the next scheduled dose. There is also a prescription-only note on the packaging. The rest of the text is not legible.*

FDA Label Image

Principal Display Panel (Carton 4mg 35ct)

LYTGOBI is a medicine available in blister cards of 35 tablets, each containing 4mg of futibatinib. A 7-day supply comes in each blister card. The tablets should be swallowed whole, and not crushed or chewed. Missing a dose for more than 12 hours requires one to resume with the next prescribed dosage. LYTGOBI does not need to be taken with food, and the patient should take one tablet every day at the same time. The rest of the text is unreadable.*

FDA Label Image

Futibatinib Str (Futibatinib Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.